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Abstract
Chromatin acetylation, a critical regulator of synaptic plasticity and
memory processes, is thought to be altered in neurodegenerative
diseases. Here, we demonstrate that spatial memory and plasticity
(LTD, dendritic spine formation) deficits can be restored in a mouse
model of tauopathy following treatment with CSP-TTK21, a small-
molecule activator of CBP/p300 histone acetyltransferases (HAT). At
the transcriptional level, CSP-TTK21 re-established half of the
hippocampal transcriptome in learning mice, likely through increased
expression of neuronal activity genes and memory enhancers. At the
epigenomic level, the hippocampus of tauopathic mice showed a
significant decrease in H2B but not H3K27 acetylation levels, both
marks co-localizing at TSS and CBP enhancers. Importantly, CSP-
TTK21 treatment increased H2B acetylation levels at decreased peaks,
CBP enhancers, and TSS, including genes associated with plasticity
and neuronal functions, overall providing a 95% rescue of the H2B
acetylome in tauopathic mice. This study is the first to provide in vivo
proof-of-concept evidence that CBP/p300 HAT activation efficiently
reverses epigenetic, transcriptional, synaptic plasticity, and behav-
ioral deficits associated with Alzheimer’s disease lesions in mice.
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Introduction
Alzheimer’s disease (AD) is characterized by the accumulation of
amyloid beta peptides and abnormally phosphorylated Tau
proteins, and a progressive impairment of plasticity and memory
functions, ending in massive neuronal loss and dementia
(Serrano-Pozo et al, 2011). Available treatments have minimal or
no effect on the course of the disease, and most advanced strate-
gies targeting the pathological hallmarks of AD (e.g., Ab
immunotherapies) have been recently proven unsuccessful
(Abbott & Dolgin, 2016; The Lancet, 2017). Alternative strategies
aim to restore neural circuits and plasticity (Canter et al, 2016).
Epigenetic changes have emerged as important contributors of
neurodegenerative diseases (Schneider et al, 2013; Coppede, 2014;
Francelle et al, 2017), including AD (Fischer, 2014; Bennett et al,
2015). Histone acetylation has been particularly studied since it is
an important regulator of plasticity and memory formation
(Peixoto & Abel, 2013; Zovkic et al, 2013). Altered acetylation
regulations are thus presumably involved in cognitive deficits. For
instance, increased histone deacetylase 2 (HDAC2) levels leading
to decreased histone acetylation have been observed at genes that
are important for learning and memory, both in mouse models of
AD and in post-mortem brains from patients with early-stage AD
(Graff et al, 2012). Hence, several histone deacetylase (HDAC)
inhibitors have been tested in different AD mouse models and
some showed significant improvement in plasticity and memory
functions (reviewed in Fischer, 2014; Graff & Tsai, 2013). Yet,
few genome-wide-scale approaches have been performed using
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brain tissues from animal models or patients affected by neurode-
generative diseases, with pioneering work coming from studies of
Huntington’s disease (e.g., Vashishtha et al, 2013; Achour et al,
2015; Bai et al, 2015; Guiretti et al, 2016), and only two studies
in AD models (Benito et al, 2015; Gjoneska et al, 2015). Tsai et al
performed a profiling of transcriptional and epigenomic changes
in the hippocampus of a mouse model of AD and showed reduc-
tion in H3K27 acetylation (H3K27ac) at downregulated genes
which were enriched in synaptic plasticity genes, as well as
increased H3K27ac at immune response-enriched upregulated
genes (Gjoneska et al, 2015). Fischer et al tested the effects of the
HDAC inhibitor suberoylanilide hydroxamic acid (SAHA) and
showed it could reinstate physiological exon usage associated
with H4K12 acetylation and plasticity gene expression in aged
neurons, but this was not found in AD neurons, where the benefi-
cial effect of SAHA was only partial (Benito et al, 2015). Thus,
mechanisms underlying epigenetic changes in AD remain cryptic
and the mode of action of potential epigenetic drugs and their
consequences in AD remain to be established.
Herein, using genome-wide-scale approaches (ChIP-seq/RNA-seq
studies), we have investigated the molecular mechanisms associated
with plasticity dysfunctions in the hippocampus of a mouse model
with AD-like Tau pathology (THY-Tau22). This mouse strain exhi-
bits neurofibrillary tangles (NFTs), neuroinflammation (Laurent
et al, 2017), spatial memory deficits (Schindowski et al, 2006),
impaired long-term depression (LTD; Van der Jeugd et al, 2011;
Ahmed et al, 2015), and altered dendritic spine formation in the
hippocampus (Burlot et al, 2015). In parallel, we have tested the
potential therapeutic application of a newly developed CBP/p300
histone acetyltransferases (HAT) activator molecule (CSP-TTK21),
as we recently showed that this molecule was able to acetylate
nuclear chromatin in the mouse brain (Chatterjee et al, 2013).
Indeed, as an alternative to HDAC inhibitors, targeting CBP/p300
HATs has been proposed as an innovative therapeutic strategy for
disorders affecting memory (Schneider et al, 2013; Valor et al,
2013). Indeed, CBP loss of function has been reported during
neurodegeneration (Rouaux et al, 2003, 2004) and CBP/p300 HATs
play important roles in neuronal plasticity and cognition, including
hippocampal long-term potentiation (LTP) and long-term memory
(Alarcon et al, 2004; Vecsey et al, 2007; Barrett et al, 2011; Valor
et al, 2011; West & Greenberg, 2011).
In this study, we found that treatment of 8-month-old THY-
Tau22 mice with CSP-TTK21 restored spatial memory and plastic-
ity functions. At this age, the hippocampal transcriptome induced
by spatial learning was severely impaired and CSP-TTK21 treat-
ment re-established the expression of genes involved in neuronal
plasticity (immediate early genes, IEGs) and of cognitive enhan-
cers (e.g., Neurotensin, Klotho). Further, we found a specific
decrease in H2B (H2Bac)—but not H3K27 (H3K27ac)—acetylation
levels in the hippocampus of THY-Tau22 mice, and CBP/p300
activation with CSP-TTK21 significantly restored this signature,
notably by a wide re-acetylation of H2B at transcription start sites
(TSS) and CBP enhancers. Together, these data indicate that CBP/
p300 HAT activation restores an epigenetic landscape that
permits, either directly or indirectly, the upregulation of genes
involved in neuronal plasticity (IEGs) and memory during learn-
ing, thus representing a promising therapeutic option for plasticity
and memory enhancement.
Results
The CBP pathway is a potential therapeutic target in a mouse
model of tauopathy
In the THY-Tau22 mouse model, the tauopathy rapidly progresses
once inflammation processes have started, around 7 months of age.
Twelve-month-old THY-Tau22 mice exhibit strong tauopathy, with
massive accumulation of abnormal Tau conformation and phospho-
rylation notably in the CA1 region of dorsal hippocampus
(Schindowski et al, 2006). We found that neurons exhibiting patho-
logical Tau hallmarks (AT100-positive neurons) showed depleted
CBP protein levels (Fig 1A). Overall, we measured a global CBP
reduction while neuronal marker NeuN levels remained unchanged,
but this was associated with an increase in astrogliosis as expected
at this age (Fig 1B). Several histone acetylation targets were evalu-
ated by Western blot analyses, and we measured a decrease in H2B
tetra-acetylation (H2BK5K12K15K20ac), whereas the global level of
the other modifications tested was unchanged (Fig EV1A). In order
to test the potential effect of our new drug, we carried out the study
at 8 months of age, an earlier symptomatic age where mice already
show memory deficits and inflammatory processes while pathology
still progresses (Schindowski et al, 2006). Transcriptomic analyses
performed in the dorsal hippocampus revealed moderate changes
(51 dysregulated genes), but confirmed the presence of the
inflammatory response signature (Fig 1C). In addition, a series of
immediate early genes (IEGs) were downregulated, suggesting
reduced basal neuronal activity in the hippocampus of THY-Tau22
vs. WT mice (Fig 1C). Lastly, predicted promoter motifs associated
with the 15 downregulated genes were associated with cAMP path-
way (ATF2/6 and CREB1; Fig 1C), which is a major regulator of
IEGs. Thus, we aimed to test CSP-TTK21 molecule treatment as
therapeutic intervention in these mice.
Spatial reference memory tested in the Morris water maze
(MWM) is a hippocampus-dependent memory task, in which 8-
month-old THY-Tau22 mice fail when the retention test is delayed
(Fig 1D). We injected mice three times with CSP-TTK21 (TAU
MOL) or the control vehicle (TAU VEH) prior to spatial training
(5-day acquisition) and tested mice at a 10-day post-training
delay. WT littermates injected with saline vehicle (WT VEH)
served as learning control. All mice showed similar acquisition
performances in escape latencies (Fig 1D) or distance to the plat-
form (Fig EV1D). Other parameters were also identical (habitua-
tion cued trial, swim speed; Fig EV1C and E). However, TAU
VEH mice showed a clear retention deficit in the probe test (WT
VEH: 23.4 vs. TAU VEH: 15.9 s in the target quadrant), which
was prevented when the THY-Tau22 mice received CSP-TTK21
treatment before training (TAU MOL: 23.4 vs. TAU VEH: 15.9 s in
the target quadrant; Fig 1D). CSP-TTK21-treated THY-Tau22 mice
were also more precise when assessing the latency to first visit to
the target quadrant (Fig EV1F) and the search strategy (see Clos-
est to mean and Best tracks Fig EV1H). Only a tendency was
measured when assessing platform crossing (Fig EV1G). Thus,
CSP-TTK21 treatment fully restored the ability to form long-term
memory in the THY-Tau22 mice. Lastly, H2BK5K12K15K20ac and
H3K27ac were still more elevated in TAU MOL vs. TAU VEH in
the hippocampus of mice euthanized 1 week after the probe test
(22 days post-injection, Fig EV1I).
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Activation of the CBP/p300 HAT pathway restores synaptic
plasticity in the hippocampus of THY-Tau22 mice
We next determined whether CSP-TTK21 treatment could affect
structural plasticity such as dendritic spine formation. Spines can be
identified based on their morphological appearance. Spines with no
head such as filopodia are considered immature. Stubby spines
show a protrusion but no head or neck and are less mature than
headed spines (thins and mushrooms) according to Harris et al
(1992). Mushroom spines are thought to be stabilized by learning
processes to form new synapses (Restivo et al, 2009; Caroni et al,
2014). We first tested the effect of CSP-TTK21 injections in the
absence of learning, in the CA1 regions of THY-Tau22 mice, that
shows diminished levels of total spines (Burlot et al, 2015): A single
CSP-TTK21 injection was able to increase the density of total spines,
with a significant impact on the stubby and filopodia sub-types (im-
mature spines, Fig 2A). We next tested the effect of CSP-TTK21
injections in response to spatial training. Learning requires the stabi-
lization, strengthening, and elimination of emerging synapses in a
time-specific manner, and synaptic rearrangements necessary for
the long-term consolidation of a memory task require 1–4 days
(Caroni et al, 2014). Therefore, mice were treated with CSP-TTK21,
trained for 4 days, and mushroom-shaped (i.e., mature) spines were
counted 4 days later. An increase in mushroom spines was observed
in the WT mice, but not in THY-Tau22 mice. CSP-TTK21 fully
restored the learning-induced spine production and maturation in
CA1 pyramidal neurons in tauopathic mice (Fig 2B). Lastly, we
tested the effect of CSP-TTK21 on long-term depression (LTD),
which is altered in THY-Tau22 mice (Van der Jeugd et al, 2011;
Ahmed et al, 2015). CSP-TTK21 treatment rescued LTD mainte-
nance in hippocampal slices (Fig 2C).
Transcriptomic effects of CSP-TTK21 in learning THY-Tau22 mice
We further checked the effect of CSP-TTK21 on gene expression. As
RNA-seq performed on tauopathic mice in basal conditions showed a
limited number of differentially expressed genes (Fig 1C), we gener-
ated RNA-seq data in CSP and CSP-TTK21-treated THY-Tau22 mice
A
B
D
C
Figure 1. Targeting the CBP/p300 pathway restores long-term spatial
memory retention in THY-Tau22 mice.
A Immunohistochemistry performed on 12-month-old THY-Tau22 mice
showing AT100-positive neurons (green), CBP-positive nuclei (red), and
DAPI-stained nuclei (blue) in the CA1 region of the dorsal hippocampus. A
representative image is shown with a focus. Scale bars: 40 and 20 lm as
noted (n = 5 mice). Arrows depict neurons bearing neurofibrillary tangles
and do not display CBP immunostaining. The star depicts a ghost tangle
(AT100-positive neuron and no nucleus).
B Western blot analyses performed in the dorsal hippocampus of 12-month-
old THY-Tau22 mice compared to age-matched controls. NeuN, actin,
tubulin, and total H2B levels are not changed. Phosphorylated Tau on
serine 404 (Tau-Ph404) attests to samples from tauopathic mice.
Quantification represents the ratio of the protein level detected on the
total amount of proteins on the membranes, with WT arbitrarily set at 1
(fold induction). Bar graphs are mean  SEM. n = 5–7/group as noted,
multiple t-tests, and CBP *P = 0.003 and GFAP **P = 0.0001 for THY-Tau
vs. WT mice.
C RNA-sequencing data performed in the hippocampus of 8-month-old mice.
Functional analyses (DAVID GOTERM) performed on significantly
deregulated genes in THY-Tau22 mice compared to WT mice.
Representative genes are presented below. |log2 Fold Change| > 0.2;
* indicates FDR < 0.05. IEG, immediate early genes. Predicted promoter
motif (right) analyses performed with GREAT. Groups: WT mice (n = 3);
THY-Tau22 mice (n = 2). Graphs are mean  SEM.
D Long-term spatial memory testing: Mice were injected three times (1 per
week) with vehicle (WT mice saline, WT VEH, n = 17), vehicle (THY-Tau22
mice CSP, 500 lg/mouse, TAU VEH, n = 10), or molecule (THY-Tau22 mice
CSP-TTK21, 500 lg/mice TAU MOL, n = 13) before training of spatial
memory in the Morris water maze (MWM); retention (Probe test) was
tested 10 days after the last training session. Acquisition (escape latencies,
seconds) and retention performances (time in target quadrant, seconds) are
shown for the three groups of mice. All groups of mice displayed significant
acquisition of the platform location [Day effect, F(4,148) = 26.45, P < 0.001;
Group and Group × Day effects, ns], but only TAU VEH exhibited impaired
retention. CSP-TTK21 treatment fully restored the ability of THY-Tau22 mice
to remember the platform location. Bar graphs are mean  SEM. Student’s
t-test to a constant value, # when compared to random (dotted line, 15 s)
WT VEH, t(16) = 4.6323, #P = 0.0002; TAU VEH, t(9) = 0.3606, P = 0.7267;
TAU MOL, t(12) = 3.945, #P = 0.0019. One-way ANOVA; F(2,37) = 3.55;
P = 0.03; * in the different comparisons: TAU MOL vs. TAU VEH,
*P = 0.0166; WT VEH vs. TAU VEH, *P = 0.040; TAU MOL vs. WT VEH, non-
significant P = 0.437). TQ, target quadrant; O, other corresponds to the
mean of the three other quadrants.
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(respectively, TAU VEH and TAU MOL) subjected to spatial learning;
WT mice being the controls (Fig 3A). In response to learning, we
found that 2,756 genes were differentially regulated in TAU VEH vs.
WT VEH mice (Fig 3B). Expression level of these genes assessed in
the different experimental groups showed that the molecule treatment
of THY-Tau22 mice (TAU MOL) tended to normalize gene expression
toward the WT WEH group (Fig 3C). In fact, only 1,716 genes were
still deregulated in TAU MOL vs.WT VEH over the 2,756 ones in TAU
VEH vs. WT VEH (Fig 3D), which corresponds to almost 50% rescue
of the transcriptome of TAU mice during learning before and after
treatment (Fig 3E). Interestingly, 180 genes were directly modulated
by the CSP-TTK21 molecule in TAU mice (Fig 3F). These results
A
B
C
Figure 2.
4 of 20 EMBO Molecular Medicine e8587 | 2018 ª 2018 The Authors
EMBO Molecular Medicine Memory recovery by CBP/p300 activation Snehajyoti Chatterjee et al
Published online: October 1, 2018 
suggest that CSP-TTK21 induced direct and indirect mechanisms that
act on the transcriptome. Lastly, learning itself induced the differential
regulation of 1,663 genes in WT mice (Fig 3G). When up- and down-
regulated genes were analyzed separately in TAU vs. WT mice (1,966
genes DOWN and 790 genes UP), fold changes observed tended
toward normalization after treatment (all the genes, Fig 3H; see the
300 most deregulated genes, Fig EV2A). Functional Biological Process
annotation showed that downregulated genes in tauopathy were asso-
ciated with ion transport, transcription, and synaptic plasticity,
whereas upregulated ones were associated with protein catabolism
(e.g. transport, ubiquitination). The treatment dramatically lowered
the significance of each of these pathways (Fig 3H). However,
CSP-TTK21 had no effect on inflammatory processes (Fig EV2B and
C) and did not affect the transgene expression (Fig EV2D).
We then evaluated direct effects of the molecule and analyzed the
98 significantly upregulated genes separately (TAU MOL vs. TAU
VEH; Fig 4). Functional enrichment analysis revealed that they were
associated with the cellular response to cAMP, which is in agreement
with the expected effect of a CBP/p300 activator (Fig 4A). They also
associated with ion-related processes (binding, transport, and chan-
nels), suggesting that CSP-TTK21 rescued part of the ion dyshome-
ostasis in the hippocampus of THY-Tau22 mice. The average
expression of these 98 upregulated genes in the TAU MOL vs. TAU
VEH comparison was then represented as a heatmap in all
◀ Figure 2. HAT activation with CSP-TTK21 treatment restores plasticity in the hippocampus of 8-month-old tauopathic mice.A The timeline of GFP-lentivirus and CSP or CSP-TTK21 (one injection, 500 lg/mouse) injection is shown. (Left) The total number of spines was significantly decreased in
TAU VEH compared to WT VEH mice. TAU MOL hippocampi showed a significant increase in the total number of spines compared to TAU VEH (one-way ANOVA
P = 0.0011, post hoc Holm–Sidak multiple-comparisons test F(2,243) = 7.03; WT VEH vs. TAU VEH, **P < 0.0009; TAU MOL vs. TAU VEH, *P = 0.0455). (Middle) Based
on spine type, the number of head spines (mushrooms, thins) was significantly lower in both TAU VEH and TAU MOL than in WT VEH controls (one-way ANOVA
P = 0.0018, post hoc Holm–Sidak multiple-comparisons test F(2,243) = 6.467; WT VEH vs. TAU VEH, *P = 0.0013; WT VEH vs. TAU MOL, *P = 0.0272. Stubby spine
density was significantly increased in TAU MOL compared to TAU VEH mice (one-way ANOVA F(2,243) = 4.311, P = 0.0145, post hoc Holm–Sidak multiple-comparisons
test: TAU MOL vs. TAU VEH, *P = 0.0109), as the number of filopodia (one-way ANOVA F(2,243) = 3.845, P = 0.0227, post hoc Holm–Sidak multiple-comparisons test
TAU MOL vs. TAU VEH, *P = 0.0179). (Right) Typical images are presented showing a dendrite fragment for each condition. White arrowhead depicts stubby spines.
Scale bar, 2 lm. Number of dendritic segments: WT VEH, n = 67; TAU VEH, n = 93, TAU MOL, n = 87; number of neurons: WT VEH, n = 20; TAU VEH, n = 28, TAU
MOL, n = 16; number of mice: WT VEH, n = 2; TAU VEH, n = 3, TAU MOL, n = 3.
B CSP-TTK21 injection into THY-Tau22 mice rescues mature dendritic spines formation in response to learning. (Top left) The timeline of injections is shown: Mice were
injected three times (1 per week) with vehicle (WT mice, WT VEH, NaCl 0.9%), vehicle [THY-Tau22 mice (TAU VEH), CSP 500 lg/mouse], or molecule [THY-Tau22 mice
(TAU MOL), 500 lg/mice] and either trained over a 4-day acquisition period in the MWM (“learning” group) or left in their home cage (“basal” group). Mushroom-
shaped spines were counted in dorsal CA1, 4 days post-training. (Bottom left) The number of mature spines was significantly increased by learning in WT VEH and
TAU MOL mice. Two-way ANOVA; learning effect, F(1,139) = 54.18; P < 0.0001; ### post hoc Holm–Sidak multiple-comparisons test: learning vs. basal in WT VEH
(P = 0.0001) and in TAU MOL mice (P = 0.0001). After learning, WT VEH and TAU MOL mice displayed significantly higher number of mature spines than TAU VEH
mice (Genotype X Treatment effect, F(2,139) = 9.704; P = 0.0001; *** post hoc Holm–Sidak multiple-comparisons test: TAU MOL vs. TAU VEH (P = 0.0001), WT VEH vs.
TAU VEH (P = 0.0001). (Right) Typical examples of a dendritic fragment bearing mushroom spines (arrows) are shown for each sub-group in response to learning.
Number of dendritic segments: Learning: WT VEH, n = 27; TAU VEH, n = 27, TAU MOL, n = 30; WT VEH_HC, n = 27; number of mice: WT VEH, n = 3; TAU VEH, n = 3,
TAU MOL, n = 3. Basal: WT VEH, n = 27; TAU VEH, n = 7, TAU MOL, n = 15; number of mice: WT VEH, n = 3; TAU VEH, n = 3, TAU MOL, n = 2.
C Mice were injected three times (1 per week) with saline (WT VEH), CSP (vehicle, VEH), or CSP-TTK21 (molecule, MOL) (500 lg/mice; THY-Tau22 mice (TAU) before
euthanasia. Long-term depression measurements were performed on hippocampal slices. (Top left) Examples of analog traces recorded 10 min before (a) and 55 min
after LTD induction (b; dotted line) in the three groups of mice. (Bottom left) Time course of LTD; LTD is expressed as a percent change in fEPSP (field excitatory
postsynaptic potentials) slope over time. After the 20-min baseline recording, a low-frequency stimulation (LFS, 2 Hz for 10 min) was applied (arrow). Recording was
stopped during the 10-min conditioning stimulation and resumed after completion of LFS. LFS induced a strong depression of the fEPSP slope, which recovered
partially to reach a stable level of depression about 20 min after stimulation. (Right) Average depression measured in the last 10 min of LTD. LTD was significantly
different in TAU VEH (88.4  4.1% of the baseline, n = 10) compared to controls (WT VEH, 71.1  4.4%, n = 9; F(1,17) = 8.8, **P = 0.008). CSP-TTK21 treatment
restored LTD to control levels (64.9  5.2%, n = 10; WT VEH vs. TAU MOL: F(1,17) = 0.83, P = 0.37, ns; TAU VEH vs. TAU MOL: F(1,18) = 13.2. **P = 0.0019).
Multivariate analyses of variance followed by post hoc test (Statview software).
Data information: Graphs are mean  SEM.
▸Figure 3. CSP-TTK21 injections of Tauopathic mice prior to learning and memory re-established part of the deregulated transcriptome.A Timeline of the experiment and experimental groups: Eight-month-old mice were injected three times (1 per week) with vehicle (WT mice, WT VEH, saline), vehicle
[THY-Tau22 mice (TAU VEH), CSP 500 lg/mouse], or molecule [THY-Tau22 mice (TAU MOL), CSP-TTK21 500 lg/mice]. One sub-group of WT mice was left in their
home cage (WT VEH_HC), and the other groups of mice (WT and THY-Tau22) were subjected to a 3-day spatial training (Learning). RNA extracts were isolated from
the dorsal hippocampus, 1 h after the last training (n = 5/group).
B Volcano plot showing that 2,756 genes are differentially regulated between THY-Tau22 and WT mice during learning. The log2(Fold-Change) was estimated by
DESeq2. FDR < 0.05 and |log2 Fold Change| > 0.2. Red dots correspond to genes with adjusted P-value < 0.05. Numbers in the corners represent the number of
downregulated (left) and upregulated (right) genes.
C Heatmap representing expression of z-score of the 2,756 deregulated genes in all experimental conditions. Color coding was performed according to the z-score of
the normalized reads counts divided by gene length. Clustering was performed using the unweighted pair group method with arithmetic mean method and
Pearson’s distance. Groups: WT VEH_HC (n = 3), WT VEH (n = 2); TAU VEH (n = 2); TAU MOL (n = 2).
D Volcano plot showing that 1,756 genes are differentially regulated between treated THY-Tau22 and WT mice during learning. Same parameters as in (B).
E Venn diagram showing the rescue of the transcriptome in learning mice, by comparing differentially regulated genes before (TAU VEH vs. WT VEH) and after (TAU
MOL vs. TAU VEH) the treatment for all genes with an adjusted P-value < 0.05.
F, G Volcano plots showing differentially regulated genes by the molecule in THY-Tau22 mice (F) and by learning in WT mice (G). Same parameters as in (B).
H Fold changes for every significant pathology-regulated gene (TAU VEH vs. WT VEH) condition are plotted for downregulations (top) and upregulations (bottom)
separately (Adjusted P-value < 0.05). Functional annotation performed with DAVID for GOTERM_Biological Process and their significance are shown on the right
before (green) and after (red) treatment. Significantly regulated pathways with log10(Benjamini P_value) < 0.05 are given.
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experimental groups (Fig 4B), showing that TAU MOL samples were
closer to WT VEH ones in learning mice. The expression of these
genes was very low in the TAU VEH mice and clustered with non-
behaving WT mice (WT VEH_HC). Not only the large majority of the
98-induced genes overlapped with those deregulated in the pathology
(81/98; Fig 4C), but a significant proportion of them was also upregu-
lated in learning conditions (34/98; Fig 4C), providing evidence that
CSP-TTK21 significantly rescued the expression of genes that are
specifically involved in learning and memory. In line, CSP-TTK21
induced the expression of a series of IEGs (e.g., Arc, c-fos, and egr1)
A
D
H
E F G
B C
Figure 3.
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in both basal and learning conditions (Fig 4D; Appendix Fig S1D and
E), suggesting that the molecule improved neuronal activity. Last,
decreased transcription of target genes, such as Klotho (Kl) and
Neurotensin (Nts), in THY-Tau22 vs. WT mice was also counterbal-
anced by CSP-TTK21 treatment in THY-Tau22 mice, up to the protein
level (Fig 4E–G). Since CSP-TTK21 did not rescue inflammatory
markers (Fig EV2A), our results further indicate that CSP-TTK21
rather modulated the expression of genes involved in plasticity and
learning and memory processes, than it acted on the pathology per se.
We also found that CSP-TTK21 reduced the expression of a signif-
icant number of genes associating with neuronal phenotype in Cellu-
lar Component annotations (Fig 5A–C). Approximately half of them
(40/82; Fig 5D) were found upregulated in THY-Tau22 vs. WT mice,
and 10% (9/82) significantly downregulated by learning (Fig 5D).
Interestingly, this functional signature also characterized the 663
downregulated genes in WT mice in response to learning (Fig 5E),
suggesting that learning induces downregulation of neuronal genes
in the dorsal hippocampus. This contrasts with the 1,000 upregu-
lated genes by learning, which were associated with transcriptional
and translational (ribosome and reticulum) processes (Fig 5F).
Altogether, our transcriptomic data support a rescued pathologi-
cal phenotype likely through activation of immediate early genes
restoring neuronal activity and induction of proteins supporting
cognitive enhancement, leading to a partial restoration of the tran-
scriptome regulated during learning.
H2B acetylation epigenetic signature is disrupted in
THY-Tau22 mice
As CSP-TTK21 activates CBP/p300 HAT function, we next investi-
gated whether it could modulate the epigenome in THY-Tau22 mice.
Among the different histones, H2B is a CBP-target in the hippocam-
pus (Alarcon et al, 2004; Barrett et al, 2011; Valor et al, 2011). In
addition, we previously showed that H2B acetylation (H2Bac) levels
were increased in the hippocampus of memory-trained rats, particu-
larly at the proximal promoter peaks of IEGs (including Fos and Egr-
1; Bousiges et al, 2010, 2013). Further, CBP/p300 HAT activation
with CSP-TTK21 molecule increased H2Bac in the hippocampus of
WT mice and induced persistence of spatial memory (Chatterjee
et al, 2013). Together, these data suggest that H2Bac levels might
represent a key regulator of hippocampal gene expression both in
resting and in learning conditions. We thus analyzed the distribu-
tion of this histone mark by ChIP-sequencing in three groups of rest-
ing mice: WT VEH, TAU VEH, and TAU MOL. Duplicates were
performed, and we also immunoprecipitated H3K27ac (Fig EV3A
and B), another known target of CBP (Jin et al, 2011; Tie et al,
2014). Compared to the whole genomic distribution, H2Bac peaks
were mainly enriched in gene profiles (introns, 42 to 29%) and
promoter regions (6 to 2%) to the cost of intergenic regions (29 to
46%; Fig 6A). These profiles were similar to that of H3K27ac except
that H2Bac was less enriched at promoter regions (6% vs. 12%).
Interestingly, H2Bac peaks were always detected when there was
H3K27ac and 43% of H3K27ac- and H2Bac-covered nucleotides co-
localized. H2Bac was strongly associated with the TSS of highly
expressed genes (Q4; Fig 6B) and gene bodies, whose main annota-
tions were related to neuronal signaling (Fig 6C). In contrast, H2Bac
was poorly found on genes related to the olfactory system that are
repressed in the hippocampus (Fig EV3C). We then compared
H2Bac enrichment in the different experimental conditions: WT
VEH, TAU VEH, and TAU MOL. When THY-Tau22 mice were
compared to WT mice, we found mainly decreased H2Bac levels, at
1,624 peaks (associated with 1,338 genes), whereas only a few
peaks (14) showed H2Bac enrichment (Fig 6D). After CSP-TTK21
injection, H2Bac was increased at 2,617 peaks (associated with
1,984 genes) in THY-Tau22 mice, whereas it was decreased at only
four peaks, indicating a substantial activation of histone acetyltrans-
ferase activity in response to CSP-TTK21 treatment (Fig 6D). Impor-
tantly, increased acetylation levels at the 1,624 decreased peaks
▸Figure 4. CSP-TTK21 injections induced the expression of 98 genes in tauopathic mice during learning.A Functional annotation charts (Benjamini, P < 0.05) using GREAT performed on the 98 significantly overexpressed genes by CSP-TTK21 treatment in tauopathic mice
(TAU MOL vs. TAU VEH). Significance is indicated as log10(Benjamini P_value).
B Heatmap representing expression z-score of the 98 significantly overexpressed genes in the TAU MOL vs. TAU VEH comparison, for all experimental conditions. Color
coding was performed according to the z-score of the normalized reads counts divided by gene length. Clustering was performed using the unweighted pair group
method with arithmetic mean method and Pearson’s distance.
C Venn diagram showing that most of the genes upregulated by CSP-TTK21 treatment were also downregulated in the pathology (81/98, P = 7.1 × 1088, v2 test), as
well as a significant overlap (P = 2 × 1029, v2 test) genes upregulated by learning in WT.
D RNA-seq data showing expression of several immediate early genes (IEGs): Nr4a1, Arc, Egr1, Dusp1, Fos, and Junb. Most of the downregulated IEGs in tauopathic
compared to WT mice present a significant induction in THY-Tau22mice after CSP-TTK21 injection. Adjusted P-values corresponding to P < 0.05 are indicated by * for
WT VEH vs.WT VEH_HC, $ for TAU VEH vs.WT VEH, and # for TAU MOL vs. TAU VEH. See Materials and Methods for statistical analyses of RNA-seq data (n = 2–3/group).
E RNA-seq data showing that CSP-TTK21 treatment of tauopathic mice restored the expression of plasticity/memory-relevant target genes: Klotho (Kl) and Neurotensin
(Nts). Adjusted P-values corresponding to P < 0.05 are indicated by * for WT VEH vs. WT VEH_HC, $ for TAU VEH vs. WT VEH and # for TAU MOL vs. TAU VEH. See
Materials and Methods for statistical analyses of RNA-seq data (n = 2–3/group).
F RT–qPCR validations performed in a different cohort of mice from the RNA-seq study (n = 4–5/group). One-way ANOVA with uncorrected Fisher’s test. Klotho, Kl:
F(3,16) = 2.949, P = 0.0643; * learning P = 0.0145 for WT VEH vs. WT VEH_HC, $ pathology P = 0.0395 for WT VEH vs. TAU VEH. Nts: F(3,14) = 4.290, P = 0.0241;
$ pathology P = 0.0036 for WT VEH vs. TAU VEH, # molecule P = 0.0081 for TAU MOL vs. TAU VEH.
G Western blot for Klotho and Neurotensin expression in the different experimental conditions. Immunoblot results are shown (n = 5/group). Bar graphs represent
the quantification of the protein levels as percentage of the control group WT VEH_HC, arbitrarily set at 100%. Each detected protein was normalized to the
corresponding amount of total proteins in the gels or the nitrocellulose membrane. Klotho and Neurotensin were further normalized to the level of actin. One-way
ANOVA with uncorrected Fisher’s test. Klotho: F(3,16) = 5.192, P = 0.0107, * learning P = 0.0117 for WT VEH vs. WT VEH_HC, $ pathology P = 0.0027 for WT VEH vs.
TAU VEH, # molecule P = 0.0282 for TAU MOL vs. TAU VEH. Nts: F(3,16) = 3.748, P = 0.0326, $ pathology P = 0.0200 for WT VEH vs. TAU VEH, # molecule P = 0.0079
for TAU MOL vs. TAU VEH.
Data information: Graphs are mean  SEM.
Source data are available online for this figure.
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were found after CSP-TTK21 treatment (Figs 6E and F, and EV3D).
By contrast, H3K27ac levels did not show any modulation at these
sites in the different experimental conditions (Fig 6E), indicating a
specific signature on H2Bac in THY-Tau22 mice. Functional enrich-
ment analyses revealed that peaks showing decreased H2Bac were
associated with genes involved in neuronal signaling pathways
(cAMP, cGMP, calcium, MAPK), LTP/LTD, and in synapses, and so
were the peaks showing increased H2Bac upon CSP-TTK21 treat-
ment (Fig 6G). These data suggest that CSP-TTK21 re-acetylated a
number of gene loci involved in neuronal functions, including
A B
C D
E
G
F
Figure 4.
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neuronal plasticity. Overall, when differentially acetylated peaks
were compared before and after CSP-TTK21 treatment, we found
that almost 95% of peaks were rescued (Fig 6H), but quite specifi-
cally as only 148 peaks remained decreased and 324 new peaks
showed increased acetylation (Fig EV3E).
We next checked the specificity of our pharmacological approach
using CBP ChIP-seq data previously generated in cortical cultures
(Kim et al, 2010) to determine H2Bac enrichment at CBP enhancers
in the dorsal hippocampus of WT mice (Fig 7A). We found that
H2Bac was globally enriched at CBP enhancers (Fig 7A; Lopez-
Atalaya et al, 2013), as well as H3K27ac, as reported in other
tissues (Kim et al, 2010; Jin et al, 2011; Malik et al, 2014; Tie et al,
2014). Importantly, H2Bac was differentially enriched at CBP
enhancers (i.e., decreased H2Bac levels in TAU VEH vs. WT VEH
A B
C D
E F
Figure 5. CSP-TTK21 injections repress the expression of 82 genes in tauopathic mice during learning.
A Functional annotation charts (Benjamini, P < 0.05) using DAVID (GOTERM_Cellular Component) performed on the 82 significantly downregulated genes by CSP-
TTK21 treatment in tauopathic mice (TAU MOL vs. TAU VEH), showing a significant association with neuronal terms. Significance is indicated as log10(Benjamini
P_value).
B Heatmap representing expression z-score of the 82 significantly downregulated genes in the TAU MOL vs. TAU VEH comparison, for all experimental conditions.
Color coding was performed according to the z-score of the normalized reads counts divided by gene length. Clustering was performed using the unweighted pair
group method with arithmetic mean method and Pearson’s distance.
C RNA-seq data showing expression of several genes belonging to “synapse” annotation (DAVID): Grik4, Homer3, and Sv2b, which are significantly downregulated by
CSPTTK21 treatment in THY-Tau22 mice. Adjusted P-values corresponding to P < 0.05 are indicated by * for WT VEH vs. WT VEH_HC, $ for TAU VEH vs. WT VEH,
and # for TAU MOL vs. TAU VEH. See Materials and Methods for statistical analyses of RNA-seq data (n = 2–3/group). Graphs are mean  SEM.
D Venn diagram showing that a significant number of genes downregulated by CSP-TTK21 treatment overlapped with genes upregulated in the pathology
(P = 2.1 × 1072, v2 test), as well as with some genes downregulated by learning in WT (P = 2.3 × 103, v2 test).
E, F Functional annotation charts using DAVID (GOTERM_Cellular Component) performed on the differentially regulated genes in learning in the WT mice condition (WT
VEH vs. WT VEH_HC). The downregulated genes by learning (E) are associated with neuronal terms, and upregulated ones (F), with transcriptional and translational
functions. Significance is indicated as log10(Benjamini P_value).
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mice and enriched H2Bac levels in TAU MOL vs. TAU VEH),
suggesting that the CSP-TTK21 molecule likely activated the HAT
function of CBP in vivo to re-acetylate H2B at CBP enhancers. Inter-
estingly, CBP enhancers could be separated into two different
classes according to the H2Bac enrichment: highly (17,817) and
poorly (23,331) enriched peaks (Fig 7B). Only highly enriched
peaks showed a differential regulation of H2Bac, and they were
associated with genes involved mainly in GO terms related to
neuronal signaling, synapse, and glutamate activity (Fig 7C). Of
note, H3K27ac peaks did not show any modulation on CBP enhan-
cers (Fig 7A). We then found that H2Bac was also differentially
enriched on TSS (Fig 7D), with a more pronounced effect on highly
expressed genes (fourth quartile; Fig EV4A), and this was not the
case for H3K27ac. Integration with transcriptomic studies showed
A
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that the TSS of differentially regulated genes, be they decreased or
increased by learning, also showed a differential H2Bac enrichment
(i.e., less H2Bac in THY-Tau22 vs. WT mice and more H2Bac after
CSP-TTK21 treatment) in their basal state (Fig 7E). This finding
suggests that a H2Bac-enriched TSS acetylation landscape is impor-
tant for further learning-induced gene regulation. We also examined
H2Bac changes in gene bodies and found a significant H2Bac
decrease in THY-Tau22 mice but no change after CSP-TTK21 treat-
ment (Fig EV4B). Significant changes, though mild, were observed
on a class of highly expressed genes (included in the fourth quar-
tile), such as the neuropilin-2 isoform 1 precursor gene (Nrp2) for
example (Fig EV4C), that presents also H3K37ac enrichment on
their gene bodies. Lastly, we identified significant changes at the c-
fos genomic locus (Fig 7F). Decreased H2Bac levels were observed
on distal and proximal c-fos enhancers (Joo et al, 2016) in THY-
Tau22 compared to WT mice, whereas they were significantly
enriched in H2Bac after CSP-TTK21 treatment, in agreement with
increased c-fos expression levels in response to learning.
Thus, the dorsal hippocampus of THY-Tau22 mice displays
decreased H2Bac levels, including at TSS, gene bodies, and CBP
enhancers of highly expressed genes. Our results further indicate
that CBP/p300 HAT activation with CSP-TTK21 restores an H2Bac
epigenetic landscape that permits, either directly or indirectly,
proper regulations of the transcriptome during learning in THY-
Tau22 mice.
Discussion
Here, we show that the CBP/p300 acetyltransferase activator CSP-
TTK21 restores neuronal activity, plasticity, and memory in an AD-like
Tau pathology mouse model. The hippocampus of THY-Tau22 mice
was characterized by a wide decrease in H2Bac levels. CSP-TTK21
treatment globally improved H2B acetylation and partly restored the
transcriptome during learning in the hippocampus of tauopathic mice,
which was sufficient to reinstate plasticity (LTD, dendritic spine
formation) and long-term memory processes. This study is the first to
identify an epigenetic signature associated with altered neuronal plas-
ticity in an AD mouse model. It is also the first to demonstrate
reversibility at the epigenomic level with a drug targeting CBP/p300
HAT’s function. Our work opens up new therapeutic options toward
the development of drugs modulating the epigenome, with HAT acti-
vators as a potent alternative to HDAC inhibitors (HDACi).
The mode of action of epigenetic modifiers in the nervous system
has been poorly investigated at the genome-wide level. A first study
used the HDACi trichostatin (TSA) in a physiological context: TSA
treatment showed a modest impact on basal hippocampal gene
expression and poorly affected the induction of IEGs by neuronal
activity (Lopez-Atalaya et al, 2013). TSA treatment preferentially
targeted already acetylated histone motifs and produced an homeo-
static response that likely prevented toxic effects induced by chro-
matin hyperacetylation. By contrast, in the pathological conditions
of tauopathy, in which a decreased acetylation is present in basal
conditions, CSP-TTK21 treatment promoted general H2B histone re-
acetylation, allowing to partly restore the transcriptome during
learning, including induction of IEGs. Early studies demonstrated
that HDACi treatment rapidly enhanced histone acetylation at Fos
and Jun loci, but resulted in a second step in their transcriptional
repression (Hazzalin & Mahadevan, 2005). In fact, transcriptional
activation requires the recruitment of both HAT and HDAC active
complexes, suggesting that the turnover of histone acetylation—as
opposed to the steady-state acetylation status—is important to
produce gene induction (Hazzalin & Mahadevan, 2005). Hence,
treatment with a HAT activator that does not inhibit HDAC activity
may here be a better therapeutic option to support neuronal activity.
Another study investigating a mouse model of aging showed that
the HDAC inhibitor SAHA restored H4K12ac levels and exon misu-
sage in hippocampal tissues (Benito et al, 2015). However, differen-
tial splicing was not affected by amyloid pathology in the brain of
APPxPS1 mice, in which SAHA also had beneficial effects, and the
exact mechanisms underlying SAHA rescue, H4K12ac deregulations,
and amyloid pathology were not established (Benito et al, 2015).
Thus, the exact mode of action of HDACi and their effects in the
brain remain elusive.
CBP is a transcriptional co-activator of neuronal gene expression
that acts through cAMP/CREB and calcium-dependent signaling
(Hardingham et al, 1999; Kim et al, 2010). A previous study demon-
strated that specific CBP delivery in the hippocampus of an AD
mouse model by gene transfer improved learning and memory func-
tions (Caccamo et al, 2010). Pharmacological CBP/p300 acetyltrans-
ferase activation using the CSP-TTK21 molecule showed spatial
memory reinforcement in normal mice (Chatterjee et al, 2013).
◀ Figure 6. H2Bac levels are severely decreased in tauopathic mice and increased by CSP-TTK21 treatment.A Pie charts showing the genomic distribution of H2Bac and H3K27ac relative to whole genome, obtained from ChIP-sequencing experiments performed in WT dorsal
hippocampus. The percentage of peaks in promoters, upstream regulatory regions (upstream;1 to20 kb relative to TSS), introns, exons, and intergenic regions is shown.
B Mean H2Bac profiles at TSS relative to gene expression obtained from RNA-seq data. Expressed genes were separated into four groups (Q1 to Q4, 6,483 genes/group),
Q1 representing the less expressed genes (0–25%) and Q4, the most expressed genes (75–100%). Profiles were established with SeqMiner centered on TSS 2 Kb.
C Mean H2Bac profiles established with SeqMiner for all genes at TSS (top) and gene bodies (bottom) for the fourth quartile (most expressed genes) in the two replicates
(rep1 and rep2). Significance (Benjamini, P < 0.05) of the annotations associated with both TSS (green) or gene profiles (red) are shown (DAVID, KEGG pathways).
D Differentially regulated H2Bac peaks were analyzed with SICER, and significant fold changes (FC > 1; FDR < 0.001) between comparisons are shown for the
pathology (TAU VEH vs. WT VEH, blue) and the effect of the molecule (TAU MOL vs. TAU VEH, red). Fold change is shown as log2 (Fold Change) (x-axis) and
significance, as log10(FDR) (y-axis).
E Mean H2Bac and H3K27ac profiles established with SeqMiner for the 1,624 decreased peaks obtained in the comparison TAU VEH vs. WT VEH. H2Bac but not
H3K27ac peaks show differential regulation.
F Time series-like plot. For every significant H2Bac decreased regions (1,624) in WT VEH vs TAU VEH, normalized read counts were computed for each of the different
conditions (WT VEH, TAU VEH, TAU MOL). Fold changes are all referring to WT VEH. Y-axis: Fold change. X-axis: Conditions.
G Functional annotation charts using DAVID performed on the differentially regulated H2Bac genes corresponding to the peaks either decreased in TAU VEH vs. WT VEH
(blue, 1,624) or increased in TAU MOL vs. TAU VEH (red, 2,617). Significance is indicated as log10(Benjamini P_value).
H Venn diagram showing the rescue of H2Bac levels by comparing differentially regulated peaks before (TAU VEH vs. WT VEH) and after (TAU MOL vs. TAU VEH) the
treatment for all peaks with an FDR < 0.001. About 95% of the peaks were not deregulated after CSP-TTK21 treatment.
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Figure 7. CSP-TTK21 treatment of THY-Tau22 mice affects the regulations of H2Bac enrichment at different genomic loci.
A Mean enrichment profiles performed with SeqMiner presenting the genomic distribution of H2Bac and H3K27ac reads obtained in ChIP-seq experiments in the
different experimental groups, established along putative neuronal CBP enhancers (4 Kb; Kim et al, 2010). In the dorsal hippocampus, H2Bac levels are enriched at
CBP enhancers in WT WEH (blue), decreased in tauopathic mice (TAU VEH, pink), and induced by CSP-TTK21 treatment (TAU MOL, green).
B Mean profiles were separated in two sets of loci, including 17,817 peaks highly enriched in H2Bac and showing a differential regulation in the experimental groups
and 23,331 peaks that were poorly enriched in H2Bac and not regulated.
C Functional annotation of the 17,817 peaks highly enriched in H2Bac performed with GREAT, GOTERM Cellular Component and Biological Process.
D Mean profiles established with SeqMiner for all genes at TSS for H2Bac (Left) and H3K27ac (Right). H2Bac but not H3K24ac presents a differential regulation at TSS.
E Mean H2Bac profiles established with SeqMiner on the differentially regulated genes obtained in transcriptomic experiments (RNA-seq), either decreased (left) or
increased (right). The “basal” H2Bac TSS enrichment state of these genes is differentially regulated whether the genes are decreased or increased in response to
learning.
F UCSC genome browser view of the c-fos genomic locus with H3K27ac ChIP-seq (blue), H2Bac ChIP-seq (green), and input (black) signals. Blue shading indicates
locations of the c-fos enhancers (Joo et al, 2016); gray shading indicates location of the promoter. Differential peaks were analyzed with SICER. This set of data shows
that H2Bac levels were significantly decreased at e1 (FDR = 1.95 × 1008), e2 (FDR = 0.0005), and e5 (FDR = 2.44 × 1005) enhancers in THY-Tau22 compared to WT
mice, and significantly enriched at e1 (FDR = 4.01 × 1008) the regions encompassing e3, e4 and TSS (FDR = 7.53 × 1007), and e5 (FDR = 0.001) after CSP-TTK21
treatment.
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Herein, we provide for the first time a proof of principle that a HAT
activator molecule is able to restore plasticity and memory functions
in a pathological brain. Treatment of THY-Tau22 mice with CSP-
TTK21 prior being challenged to spatial training promoted the
upregulation of genes enriched in the cAMP signaling pathway,
including IEGs, and in ion channel/transporter activity functions, in
agreement with a role of CBP/p300 in the regulation of ion home-
ostasis and neuronal excitability. Importantly, CSP-TTK21 counter-
balanced the transcription of downregulated genes in THY-Tau22
mice that have been previously associated with improved cognitive
functions: Klotho and Neurotensin, a result that we could validate at
the protein level. Klotho was first described to counteract aging, and
more recently, showed beneficial effects in a mouse model of AD
(Kurosu et al, 2005; Kuang et al, 2017; Leon et al, 2017; Masso´
et al, 2017). The neurotensin system is altered in the temporal lobe
of AD patients (Gahete et al, 2010), and APP/PS1 mice microin-
jected with Neurotensin show improved spatial memory functions
and neuronal excitability (Xiao et al, 2014). Altogether, these data
support a mechanistic model in which activation of the acetyltrans-
ferase CBP in a diseased brain can re-establish functional neuronal
networks through induced expression of genes involved in neuronal
stimulation (IEGs, cAMP pathway, ion homeostasis) and important
cognitive enhancers.
An important finding is that we established an epigenetic signature
associated with H2Bac in the hippocampus of cognitively deficient
tauopathic mice. Very few studies investigated histone acetylation in
pathological context at the genome-wide level. Our recent studies
showed selective decreased H3K27ac at neuronal identity genes regu-
lated by a super-enhancer, in the striatum of Huntington’s disease
mice (Achour et al, 2015; Le Gras et al, 2017). In the hippocampus of
the CK-p25 AD mouse model, H3K27ac levels were decreased at
promoter/enhancers of genes associated with synapse and learning
functions and preferentially bound by CBP (Gjoneska et al, 2015).
Our data show for the first time a significant alteration of H2Bac levels
in mice bearing AD Tau hallmarks. As H3K27ac levels between THY-
Tau22 and WT mice were unchanged, we suggest that H2Bac loss
may be an early mark of a disease state in the hippocampus.
Few studies have investigated H2Bac genomic distribution in
normal tissue. A previous study reported that H2Bac profile mostly
covers intragenic regions and promoters in hippocampal tissues
(Lopez-Atalaya et al, 2013). They also found H2Bas enrichment at
CBP enhancers, also defining H2B as a preferred target mark for
CBP (Alarcon et al, 2004; Valor et al, 2011). Here, we confirm this
genomic distribution and precisely show that acetylation of H2B N-
terminus is enriched at the TSS of the 50% mostly expressed
hippocampal genes (Fig 6B). H2BK5ac has already been reported as
an important modification associated with active gene transcription
in other tissues/cell types (Karlic et al, 2010). Moreover, H2BK20ac
was recently suggested to contribute to cell type–specific gene regu-
lation and biological functions through distal and proximal cis-regu-
latory elements (Kumar et al, 2016). Thus, the decrease in H2Bac in
THY-Tau22 hippocampus may have deleterious functional conse-
quences. Yet, the severe H2Bac decrease observed in mice with a
conditional knock-down of CBP (CBP cKO mice) was not sufficient
to induce memory deficits (except for novel object recognition) or
neuronal death (Valor et al, 2011). In our tauopathy model,
decreased H2Bac and CBP levels are only part of the pathological
process, which also includes neuroinflammation in contrast to
CBPcKO mice. H2Bac loss in THY-Tau22 mice may thus synergize
with other dysfunctions.
Remarkably, CSP-TTK21 treatment of THY-Tau22 mice resulted in
a global increase in H2Bac acetylation at TSS, CBP enhancers (Kim
et al, 2010). It is noteworthy that deregulated peaks (presenting a
decrease in H2Bac enrichment in tauopathic mice and an increase by
the treatment) were associated with genes involved mainly in GO
terms related to neuronal signaling pathways—including cAMP and
calcium, glutamatergic synapse, and LTP/LTD processes—all of these
pathways being dysregulated in tauopathic mice (Van der Jeugd et al,
2011; Ahmed et al, 2015; Burlot et al, 2015). This suggests a link
between the restoration of H2Bac levels in the hippocampus and that
of hippocampal functions (i.e., spatial memory formation, LTD,
dendritic spine formation). However, all these genes were not deregu-
lated in terms of gene transcription in basal conditions. In addition,
deregulated transcription in THY-Tau22 compared to WT mice in
learning conditions also lacked correlation with H2Bac enrichment in
the basal state, as they followed the same pattern of enrichment (de-
creased in tauopathic mice and increased by the molecule) whether
they were transcriptionally up- or downregulated after learning
(Fig 7E). This indicated that gene transcription per se is not solely
dependent on H2Bac enrichment. It seems more likely that CBP/p300
HAT activity maintains a balanced H2Bac epigenomic landscape in the
hippocampus, which may contribute to acetylation homeostasis neces-
sary for neuronal functions. A lack of clear correlation between acety-
lation levels at specific genes and their transcriptional status has been
reported previously, either in learning and memory (Lopez-Atalaya &
Barco, 2014; Halder et al, 2016) or in response to HDAC inhibition
(Lopez-Atalaya et al, 2013). A growing body of evidence suggests that
the specific genomic topologies favor correct spatiotemporal gene
expression programs in response to challenge (Mitchell et al, 2014;
Madabhushi et al, 2015; Watson & Tsai, 2017) and the CBP/p300-
H2Bac balance may be an important player in such mechanisms.
Lastly, how such epigenetic dysfunction relates to Tau pathologies
is still an open question. Interestingly, Tau protein is found in the
nucleus (Wei et al, 2008; Sultan et al, 2011; Qi et al, 2015), a cellular
compartment where Tau levels progressively increase during aging
(Gil et al, 2017). On the one hand, nuclear Tau physiological functions
were recently proposed to participate in the maintenance of pericentric
heterochromatin integrity (Mansuroglu et al, 2016). On the other
hand, H2B overexpression was shown to deregulate heterochromatin
architecture (Ito et al, 2014; Medrano-Ferna´ndez & Barco, 2016).
Further experiments are therefore required to understand whether
pathological nuclear Tau accumulation can (directly or indirectly) alter
euchromatin topology, H2Bac levels, and CBP-dependent regulations.
In conclusion, this study identifies that pharmacological activa-
tion of CBP/p300 HAT function with a new epi-drug (CSP-TTK21)
stands as a therapeutic option for AD-related disorders. Indeed,
CSP-TTK21 treatment restored plasticity in the diseased brain of
mice presenting an AD-like Tau pathology. One reason why most
AD clinical studies may have failed is that cognitive dysfunctions
associated with AD patients emerge late in the progression of the
disease, when the brain is already affected by amyloid b deposition,
neurofibrillary tangles, and cell death (Hyman et al, 2012). The
possibility to reinstate some plasticity in affected brains by activat-
ing the acetyltransferase function of CBP/p300 could lead to more
successful therapeutic options that may delay the cognitive decline
and improve the condition of AD patients.
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Materials and Methods
Animals
Heterozygous THY-Tau22 transgenic mice were bred on a C57BL6/J
background. THY-Tau22 mice overexpressed mutated human Tau
protein (G272V and P301S) under the control of a Thy1.2 promoter
allowing a specific neuron expression that starts at postnatal day 6
(Schindowski et al, 2006). All mice used in this study were 8-month-
old male mice, except in Fig 1A and B in which we used 12-month-
old male mice and in one H2Bac ChIP-seq replicate, where we used
8-month-old female mice. All animals were kept in standard animal
cages under conventional laboratory conditions (12-h/12-h light–
dark cycle, temperature: 22°C 2, humidity: 55% 5) with ad libi-
tum access to food and water. All behavior experiments were
conducted between 9:00 and 12:00 am. Experimental protocols and
animal care were in compliance with the institutional guidelines
(council directive 87/848, October 19, 1987, Ministe`re de
l’agriculture et de la Foreˆt, Service Ve´te´rinaire de la Sante´ et de la
Protection Animale) and international laws (directive 2010/63/UE,
February 13, 2013, European Community) and policies (personal
authorizations #67-117 for A.-L.B., and #I-67UnivLouisPasteur-F1-04
for R.C.). Our project has been reviewed and approved by the ethics
committee of Strasbourg, France (#AL/100/107/02/13 and
APAFIS#5118-2016042017216897v9).
Drug production, testing, and treatment
See Appendix Supplementary Methods and Fig S2, and also Chatter-
jee et al (2013).
Morris water maze evaluations
Atlantis MWM tank was placed in a room with several visual extra
maze cues. Water opacified with powdered chalk (Blanc de
meudon) was maintained at 21°C. Mice were habituated to the set-
up for two consecutive days (habituation 1 and 2). During habitua-
tion 1, mice were allowed to discover the pool filled with 5 cm
height of water and a visible platform during 60 s. During habitua-
tion 2, mice were allowed to swim in the pool filled with water and
without a platform for 60 s. Mice were trained for the next 5 days
(acquisition 1–5) to locate a hidden platform beneath the water
using spatial cues present in the room. Each acquisition day
consisted of four trials of maximum duration of 60 s in each trial.
Each trial concluded immediately after mice reached the platform
or after the completion of 60 s. Mice failing to find the platform
were gently guided to reach the platform and was allowed to stay
for 8–10 s. Probe test was performed 10 days after the last training
day. During the probe test, the platform was removed and mice
were placed at the center of the pool and allowed to swim for 60 s.
The different parameters (distance, time, etc.) were recorded by a
video tracking system (ANY-maze). The experimenter was blind to
genotype and treatment. The mice were uniquely identified accord-
ing to an identification chip. Mice were randomly distributed as
their order of passage in the Morris water maze during the different
days of training (so that they do not perform the tap.22.sk always
at a given time). Genotype and treatment were uncovered before
analyses.
Statistics
For behavioral data, we have used a sample size to more than 10.
Exclusion/inclusion criteria: Outliers were defined as results dif-
fering from the mean by 3 SD. Stressed mice were defined upon
ethical criteria: stayed immobile in the cage or showed aggressive
behavior. A floating behavior in the Morris water maze was defined
as a floating during more than 30s/assay of 60s. These mice were
excluded from the experiment and usually represented on average 1
per experiment. One- or two-way ANOVA was used for data analysis
with repeated measures when appropriate. Escape latencies
recorded during acquisition were analyzed using ANOVA, followed
by Newman–Keuls multiple-comparisons test when appropriate. For
the probe tests, the time spent in the target quadrant was compared
with the chance level (15 s for a test duration of 60 s in four quad-
rants) using a one-sample Student’s t-test. ANOVA factorial was
used to analyze the “treatment” and “genotype” effect for the time
spent in the target quadrants and the average time in the other three
quadrants. Results were expressed as means of +SEM. Values of
P < 0.05 were considered as statistically significant.
Immunohistochemistry
For heat-induced epitope retrieval, floating sections were kept in
sodium citrate (pH 6, 10 mM, 37°C, 30 min). After permeabilization
(PBS1X/Triton X-100 2%, 15 min), unspecific labeling was blocked
(PBS1X/Triton X-100 0.1%/horse serum 5%, 1 h at RT) and slices
were incubated overnight with polyclonal anti-CBP antibody (1/50;
ab2832; Abcam), washed, and further incubated with anti-rabbit
Alexa Fluor 594 (red, 1/1,000) antibody (Invitrogen, Thermo Fisher
Scientific) for 1 h. IHC was performed sequentially and the second
antibody was added in a second step. Slices were incubated over-
night with monoclonal anti phospho-Tau (Thr212, Ser214) antibody
(1/1,000; AT100, MN1060 Thermo Fisher Scientific), washed, and
further incubated with anti-mouse Alexa Fluor 488 (green, 1/1,000)
antibody (Invitrogen, Thermo Fisher Scientific). Slices were incu-
bated with the Hoechst dye 33342 (1 mg/ml; 5 min) and mounted
in Mowiol for observation. Acquisitions were performed using a flu-
orescence microscope coupled with an ApoTome module (Zeiss).
Photomicrographs were captured using the z-stack mode with
0.5 lm of thickness between slices, 18 in-depth slices were taken
and flattened using the maximum intensity projection (MIP).
Biochemical analyses
Mice were either left in their home cage (basal conditions) or
trained for three consecutive acquisition days for spatial reference
memory in the Morris water maze and left in their home cage for
1 h after the last trial (learning conditions). Mice were killed by
cervical dislocation, the brains were extracted, and the dorsal
hippocampus was immediately dissected out, flash-frozen in liquid
nitrogen, and stored at 80°C. The time at which the mice were
killed was randomized according to their experimental group and
was consistently performed between 9:00 and 11:00 am.
Western blot analyses
Dorsal hippocampi were finely chopped on ice using a razor blade
and homogenized in Laemmli buffer with a disposable pestle in
microcentrifuge tubes. Tissues were sonicated for 15 s twice
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(ultrasonic processor, power 40%) followed by heating at 70°C for
10 min. Lysates were centrifuged at 20,000 g for 5 min, and super-
natant was stored at 80°C until use. Estimation of the protein
concentration in the lysate was determined by using RC-DC Protein
Assay (Bio-Rad) kit. Proteins were loaded on Midi-PROTEAN TGX
Stain-FreeTM Precast Gels (26 wells, 4–20%, Bio-Rad). The use of
stain-free imaging allows for the normalization of bands to the total
protein on a blot. A UV-induced 1-min reaction of the gels after
protein migration produces fluorescence. The fluorophores remain
covalently bound to the proteins throughout blotting and may be
subsequently visualized in gels or on the nitrocellulose membranes
for validation in the Western blotting workflow. Antibodies used for
Western blots were acetyl-histone H2BK5 (1/1,000; #07-382; Milli-
pore), acetyl-histone H2BK5K12K15K20 (1/1,000; #07-373; Milli-
pore), H3 histone (1/2,000; #ab1791; Abcam), acetyl-histone
H3K9K14 (1/1,000; #06-599; Millipore), histone H2B (1/4,000; #H2-
28; Euromedex), acetyl-histone H3K27 (1/2,000; #ab4729; Abcam),
acetyl-histone H4 (1/4,000; #39165, Active motif), Phospho-Tau
(Ser404) (1/1,000; #44-758G, Thermo Fisher Scientific), Tau 5 (1/
1,000; #AHB-0042, Invitrogen), CBP (1/500; #sc-369, Santa Cruz
Biotechnology), GFAP (1/2,000; #MAB360; Millipore), Neurotensin
(1/1,000; #BML-NA1230; Enzo Life Sciences); Klotho (1/5,000;
#AF1819,R&D Systems), actin (1/1,000; #A2066; Sigma). HRP
conjugated secondary antibodies against mouse and rabbit (Jackson
ImmunoResearch). Blots were revealed with ECL (Clarity, Bio-Rad)
with a ChemiDoc Touch system (Bio-Rad). Results were quantified
using ImageLab software.
RNA extractions
Total RNA was extracted from the dorsal hippocampal tissues using
TRIzol reagent (Invitrogen). Freshly dissected tissues were chopped,
homogenized in 400 ll of TRIzol reagent, and frozen (20 min at
80°C), followed by 3-min centrifugation at 14,000 g before chloro-
form/isoamyl extraction. DNA precipitation was performed on the
supernatant using isopropanol and RNase-free glycogen (10 min at
RT). The pellet was washed once with 70% ethanol and resuspended
in Milli-Q water for DNAse treatment (30 min at 37°C). RNA samples
were further purified using a phenol/chloroform extraction, followed
by a new precipitation (overnight at 20°C, with 100% ethanol, 3 M
NaOAC). After two last 70% ethanol washes, pellets were air-dried
and resuspended in 30 ll nuclease-free Milli-Q water, heated 6 min
at 50°C, and RNA concentration estimation was performed.
Real-time qRT–PCR analyses
Samples with OD260/280 and OD260/230 ratio close to 2.0 were consid-
ered for cDNA synthesis. 0.5–1 lg of total RNA was reverse-tran-
scribed (iScript cDNA synthesis kit; Bio-Rad). Bio-Rad iCycler
System (CFX) was used to perform qPCR using SsoAdvanced SYBR
Green SuperMix (Bio-Rad). A specific standard curve was performed
in parallel for each gene, and technical duplicates were performed.
The conditions for qRT–PCR were 3 min at 94°C, followed by 40
cycles of 45 s at 60°C and 10 s at 94°C. Data were analyzed by gene
regression using iCycler software and normalized to housekeeping
genes (RNA polymerase II, 36B4) levels.
Statistics for biochemical studies
For these studies, we have tried to always have n values > 5. For
Western blot studies comparing WT to THY-Tau22 mice, inclusion
was verified by performing an immunostaining against a pathologi-
cal form of Tau protein (Tau5, Tau-Ph404). All samples were used
until exhaustion which explains some variability in the number of
Western blot samples (n = 5–7). For RT–qPCR validation experi-
ments, all samples (n = 5) were included. All statistical analysis
involving three groups (WT, THY-Tau22 CSP, and THY-Tau22 CSP-
TTK21) were performed using ANOVA followed by uncorrected
Fisher’s for multiple-comparisons tests. For comparison between
two groups, Student’s t-test was performed. Data were expressed as
the mean + SEM. The significant level was set at P < 0.05.
Dendritic spines labeling and counting after GFP staining
Stereotaxic injections of lentivirus-GFP
See Appendix Supplementary Methods.
Immunohistochemistry
Mice were deeply anesthetized with pentobarbital (50 mg/kg) and
transcardially perfused with PB (0.1 M phosphate buffer) followed
by cold 4% paraformaldehyde in PB (PFA). Brains were removed
and fixed overnight in 4% PFA and subsequently merged in 30%
sucrose solution at 4°C until the brain sank. Brains were cut on a
freezing microtome into 50-lm-thick coronal sections covering the
whole hippocampus. Sections were kept in cryoprotectant [0.1 M
PB, 0.15 M NaCl, 30% (v/v) ethylene glycol, 30% (v/v) glycerol]
at 20°C until immunostaining. For immunostainings, free-
floating brain sections were extensively rinsed in PBS-T (0.25%
Triton X-100 in PBS; 137 mM NaCl, 2.7 mM KCl, 10 mM
Na2HPO4, 1.8 mM KH2PO4) and incubated overnight in the
following primary antibodies at 4°C: goat anti-GFP (Rockland,
1:500) and mouse anti-NeuN (Millipore, 1:1,000) diluted in PBS-
T. Brain sections were rinsed and incubated for 1 h at room
temperature with, respectively, donkey anti-goat Alexa 488-conju-
gated and donkey anti-mouse Alexa 555-conjugated (Life Tech-
nologies; all diluted 1:500 in PBS-T). After several rinses, brain
sections were mounted in Hoechst mixed in Mowiol (Life Tech-
nologies; 1:10,000), coverslipped, and kept at 4°C. Images of basal
dendritic segments of GFP-labeled CA1 pyramidal neurons were
acquired using a confocal microscope (Leica TCS SP8; Leica,
Heidelberg, Germany) equipped with 63× HCX PL APO (1.40 NA)
objective (Toulouse Re´seau Imagerie, FRBT-CBD). The laser
power, photomultiplier gain, and offset were kept constant for
every image. Four images of 1,024 × 1,024 pixels were acquired
at 8,000 Hz scanning speed and averaged to increase the signal-
to-noise ratio. Dendritic spine images were acquired in z-series at
0.19-lm interval. The voxel size was 30.06 nm in x–y directions
and 193.81 nm in z-direction. Stack images of 12-bit files were
deconvolved with Huygens Essential deconvolution software (SVI)
with five iterations and images were imported into Imaris XT (Bit-
plane AG) for analysis.
Dendritic spines labeling and counting after Golgi staining
Mice that had underwent a 4-day training in the MWM were killed
4 days later. The Rapid Golgi stain kit (FD Neurotechnologies, Inc.)
was used according to the manufacturer’s instructions. Freshly
dissected brains were immersed in solution A and B for 2 weeks at
room temperature and were then transferred to solution C for
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another 24 h at 4°C. 150-lm-thick coronal sections containing the
rostro-caudal axis of hippocampal region CA1 were made using a
Vibratome (VT1000M; Leica). Images were acquired using a bright-
field microscope equipped with automated motorized stage and
MorphoStrider software (Explora Nova, La Rochelle, France). 63×
magnification images were taken from secondary and tertiary
dendrites from CA1 pyramidal neurons. For each genotype, condi-
tion and treatment 8–10 dendritic segments per animal were
analyzed.
Quantification of dendritic spines
Dendritic spines were defined as protrusions from the dendritic shaft
and identified based on their morphological appearance. Spines
were classified into three different types according to Harris et al
(1992): head spines (protrusion with neck and head), stubby (pro-
trusion with no obvious neck or head), and filopodia (protrusion
with long neck and no head). For each animal, 24–35 dendritic
segments were analyzed from 5 to 10 neurons. The spine density
was presented as the number of spines per 1 lm of dendritic length.
Statistics
Dendritic spines counting scores were from about 25 (Golgi stain-
ing) and 70 (GFP lenti) dendritic segments which were from mate-
rial of 15–30 neurons and two to three animals/condition. Data are
presented as mean  SEM. For GFP staining, Kolmogorov–Smirnov
test was performed on each data set to test the distribution normal-
ity. Statistical analyses were run with Prism software (GraphPad
5.0). Dendritic spine analyses were compared across groups by
means of one-way ANOVA followed by post hoc analyses that were
performed using Holm–Sidak multiple-comparisons tests. For Golgi
staining, dendritic spines were compared across different groups by
using a two-way ANOVA followed by Newman–Keuls multiple-
comparisons tests.
Ex vivo electrophysiology (LTD)
Mice were anesthetized with halothane and decapitated. The brain
was rapidly removed from the skull and placed in chilled (0–3°C)
artificial cerebrospinal fluid (ACSF) containing 124 mM NaCl,
3.5 mM KCl, 1.5 mM MgSO4, 2.5 mM CaCl2, 26.2 mM NaHCO3,
1.2 mM NaH2PO4, and 11 mM glucose. Transverse slices (300–
400 lm thick) were cut with a tissue chopper and placed in ACSF in
a holding chamber, at 27°C, for at least 1 h before recording. Each
slice was individually transferred to a submersion-type recording
chamber and submerged in ACSF continuously superfused and equi-
librated with 95% O2, 5% CO2. For electrophysiological recordings,
a single slice was placed in the recording chamber, submerged, and
continuously superfused with gassed (95% O2, 5% CO2) ACSF (28–
31°C) at a constant rate (2 ml/min). Extracellular field excitatory
postsynaptic potential (fEPSPs) were recorded from the apical
dendritic layer of the CA1 area, using a glass micropipette filled with
2 M NaCl. fEPSPs were evoked by the electric stimulation of Schaffer
collaterals⁄commissural pathway at 0.1 Hz with a bipolar tungsten
stimulating electrode placed in the stratum radiatum (100 ls dura-
tion). The averaged slope of three fEPSPs was measured using p-
clamp software (Axon Instruments) for 20 min before conditioning
stimulation. Long-term depression (LTD) was induced by applying a
low-frequency stimulation at 2 Hz (1,200 pulses for 10 min). The
sequence was repeated three times, with an interburst interval of
10 s. Testing with a single pulse was resumed for 60 min to deter-
mine the level of LTD. Any change in synaptic strength was
expressed relative to the control level (100%).
Statistics
Average values of the fEPSP slope were calculated for the last 10 min
and expressed as a percentage of the baseline response (% base-
line)  SEM. In order to take into account the correlations inherent to
repeated measures in electrophysiological recordings, P-values were
calculated using multivariate analyses of variance followed by post
hoc unpaired Student’s t-tests using StatView software. In all cases, dif-
ferences were considered significant when P ≤ 0.05.
RNA libraries and sequencing
RNA-seq libraries (n = 3/group) were generated from 300 ng of
total RNA Illumina TruSeq RNA Sample Preparation Kit v2 (Part
Number RS-122-2001). Briefly, following purification with poly-T
oligo-attached magnetic beads, the mRNA was fragmented using
divalent cations at 94°C for 2 min. The cleaved RNA fragments were
copied into first-strand cDNA using reverse transcriptase and
random primers. Second-strand cDNA were synthsized using DNA
Polymerase I and RNase H. Following the addition of a single “A”
base and subsequent ligation of the adapter on double-stranded
cDNA fragments, the products were purified and enriched with PCR
[30 s at 98°C; (10 s at 98°C, 30 s at 60°C, 30 s at 72°C) × 12 cycles;
5 min at 72°C] to create the cDNA library. Surplus PCR primers
were further removed by purification using AMPure XP beads
(Beckman Coulter), and the final cDNA libraries were checked for
quality and quantified using capillary electrophoresis. Sequencing
was performed on the Illumina Genome Hiseq2500 as single-end 50
base reads following Illumina’s instructions.
RNA-sequencing analyses and statistics
Reads were mapped onto the mm9 assembly of mouse genome using
TopHat v2.0.10 (Kim et al, 2013) and the bowtie v2.1.0 aligner. Gene
expression was quantified from uniquely aligned reads using HTSeq
v0.5.4p3 (Anders et al, 2013) and gene annotations from Ensembl
release 67. Read counts were normalized across libraries with the
method proposed by Anders and Huber (2010). Statistical analysis
was performed with the method proposed by Love et al (2014)
implemented in the DESeq2 Bioconductor library (v1.0.19). Result-
ing P-values were adjusted for multiple testing by using the Benja-
mini and Hochberg (1995) method. Heatmaps were performed with
R (heatmap.2 function, Euclidean distance, and complete linkage
were used to perform gene clustering). Heatmap representing expres-
sion z-scores calculated as row Z score = [(Value) – Mean (Row)]/
[Standard deviation (Row)]. Cross-comparison of RNA-seq data was
performed using Venny 2.1 (Oliveros, 2007–2015). Gene ontology
(GO) analyses for functional enrichments were performed using the
tools DAVID (da Huang et al, 2009) and/or GREAT (McLean et al,
2010). For analyses with GREAT, defaults setting were used. Whole
Mouse genome (mm9) was used as background. Top-enriched terms
are shown (P-values < 0.05 were considered).
For RNA-seq analyses presented in Fig 3, three out of 12 samples
were excluded because a great variability was seen in the heatmaps
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quantifying the global RNA-seq sample differences, likely due to
genetic derivation; of note, these three mice—that had been randomly
assigned to an experimental condition—originated from the same litter
out of five litters total. These criteria were decided a posteriori.
ChIP experiments
Freshly dissected tissues were chopped with a razor blade and
rapidly put in 1.5 ml PBS containing 1% formaldehyde for 10 min
at room temperature (RT) followed by the addition of glycine
(0.125 M final concentration). Dorsal hippocampi from eight mice
were pooled per sample. Tissue samples were then processed as in
Bousiges et al (2010) and sonicated with a Diagenode Bioruptor (35
cycles with 30-s ON/30-s OFF on High Power). Sonicated chromatin
was centrifuged 10 min at 14,000 g, and the supernatant was
collected and diluted 10 times in ChIP dilution buffer (0.01% SDS,
1.1% Triton X-100, 1.2 mM EDTA, 16.7 mM Tris-Cl, pH 8.1,
167 mM NaCl). A fraction of supernatant (50 ll) from each sample
was saved before IP for “total input chromatin”. Supernatants were
incubated overnight (4°C) with 1/1,000 primary antibody
[H2BK12K15ac (ab1759), H2BK5ac (07-382); H3K27ac (ab4729)],
followed by protein A Dynabeads (Invitrogen) for 2 h at RT. After
several wash steps (with low salt, high salt, LiCl, and TE buffers),
complexes were eluted in 300 ll elution buffer (1% SDS, 0.1 M
NaHCO3). The crosslinking was reversed (overnight at 65°C), and
the DNA was subsequently purified with RNase (30 min, 37°C),
proteinase K (2 h, 45°C), phenol/chloroform, and chloroform/
isoamyl extractions. After overnight ethanol precipitation (at
20°C), two last 70% ethanol washes were done before air drying
the resulting DNA pellet. The pellets were resuspended in 30 ll
nuclease-free Milli-Q water, and the supernatant was transferred in
low binding tubes and brought to the sequencing platform for DNA
concentration estimation (Qubit fluorometric quantitation).
ChIP-seq libraries
ChIP-seq libraries were prepared using NEXTflex ChIP-seq Kit
(#5143-02, Bioo Scientific) following the manufacturer’s protocol
(V12.10) with some modifications. Briefly, 10 ng of ChIP-enriched
DNA or input DNA was end-repaired using T4 DNA polymerase,
Klenow DNA polymerase, and T4 PNK, then size-selected, and
cleaned-up using Agencourt AMPure XP beads (#A63881, Beckman).
A single “A” nucleotide was added to the 30 ends of the blunt DNA
fragments with a Klenow fragment (30 to 50exo minus). The ends of
the DNA fragments were ligated to double-stranded barcoded DNA
adapters (NEXTflex ChIP-seq Barcodes-6, #514120, Bioo Scientific)
using T4 DNA Ligase. The ligated products were enriched by PCR
[2 min at 98°C; (30 s at 98°C, 30 s at 65°C, 60 s at 72°C) × 14 cycles;
4 min at 72°C] and cleaned-up using Agencourt AMPure XP beads.
Prior to analyses, DNA libraries were checked for quality and quanti-
fied using a 2100 Bioanalyzer (Agilent). The libraries were loaded in
the flowcell at 8 pM concentration, and clusters were generated
using the Cbot and sequenced on the Illumina Genome Hiseq2500 as
single-end 50 base reads following Illumina’s instructions. Image
analysis and base calling were performed using RTA and CASAVA.
ChIP-sequencing analyses
Reads were mapped onto Mouse reference assembly mm9/NCBI37
using bowtie v0.12.7 aligner (Langmead et al, 2009). Peak detection
of H2Bac and H3K27ac was performed using SICER v1.1 (Zang et al,
2009) with the following parameters: window size: 200; gap size:
1,000 for H2Bac; and 600 for H3K27Ac. Peaks were annotated rela-
tive to genomic features using Homer (Heinz et al, 2010) with anno-
tation from Ensembl v67. Differential peaks were analyzed using
SICER with the SICER-df.sh script. Global comparison of samples
and clustering analysis were performed using seqMINER (Ye et al,
2011). As reference coordinates, we used RefSeq genes for Mouse
mm9 genome. Increased and decreased regions were selected if their
P-values < 105. Biological duplicates were performed for the H2Bac
mark. They were analyzed independently in the same manner, and
only differential peaks replicating were further analyzed (Fig EV3A
and B). Inputs were used as controls.
Integrated analysis of RNA-seq and ChIP-seq data was done using
the open Galaxy platform GalaxEast (http://www.galaxeast.fr).
Nucleotide coverage between H2Bac and H3K27ac was calcu-
lated using bedtools jaccard (bedtool Fisher exact test, P-value = 0).
Normalization of ChIP-seq data
ChIP-seq data were normalized based on a method that consists of
equalizing background regions. Briefly, read counts were computed
in all regions of 5,000 nt in length of the mouse genome (mm9
assembly) for each of the samples to normalize. Read counts were
then compared across samples and used to estimate a scaling ratio.
Finally, the scaling ratio was used to remove randomly chosen reads
in the samples to be normalized.
Data availability
The datasets produced in this study are available in the following
databases:
• RNA-seq data: Gene Expression Omnibus GSE103359 https://
www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE103359
The paper explained
Problem
Alzheimer’s disease (AD) is a neurodegenerative disease first affecting
memory functions and progressively leading to massive neuronal loss
and dementia. There is currently no cure, and some recent clinical
trials failed.
Results
Chromatin acetylation, a critical regulator of synaptic plasticity and
memory processes, is thought to be altered in neurodegenerative
diseases. Our study provides evidence of acetylation dysregulations in
an AD-like Tau pathology mouse model. It further brings an in vivo
proof of concept that a treatment with a CBP/p300 acetyltransferase
activator molecule (CSP-TTK21) efficiently restores neuronal activity,
plasticity, and memory in this mouse model, together with molecular
evidence of rescued acetylation in the brain.
Impact
The possibility to reinstate some plasticity in affected brains by acti-
vating the acetyltransferase function of CBP/p300 could lead to more
successful therapeutic options that may delay the cognitive decline
and improve the condition of AD patients.
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• ChIP-seq data: Gene Expression Omnibus GSE103358 https://
www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE103358
Expanded View for this article is available online.
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